Bio-Rad Introduces Anti-Ipilimumab Antibodies

HERCULES, Calif., April 21, 2020 – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, has extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of antibodies that are specific for ipilimumab (Yervoy) and the ipilimumab/CTLA-4 drug-target complex. These highly specific and high-affinity antibodies are suitable for bioanalytical and patient drug level monitoring assays for the immune checkpoint inhibitor: ipilimumab.

Bio-Rad offers a portfolio of recombinant, monoclonal anti-idiotypic antibodies and drug-target complex binders for the development of highly selective and sensitive assays to support researchers in developing robust methods in a short timescale and generating translatable and defensible results.

Ipilimumab activates the immune system by inhibiting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), a protein receptor that hinders the destruction of cancerous cells, to treat cancers such as melanoma. The four anti-ipilimumab antibodies inhibit the binding of the drug to its target, CTLA-4, and therefore detect free drug. These antibodies are suitable for developing pharmacokinetic (PK) bridging ELISAs and being used as a surrogate positive control (or reference standard) for anti-drug antibody assays. The drug-target complex binder specifically recognizes the ipilimumab/CTLA-4 complex and can be used as the detection antibody in a PK antigen capture assay as an alternative format to the bridging ELISA.

The recombinant monoclonal anti-idiotypic antibodies are generated using the Human Combinatorial Antibody Library (HuCAL^®) and CysDisplay^®, a proprietary method of phage display with guided selection methods to obtain highly targeted reagents. The recombinant production method also ensures a consistent and secure supply.

“Bio-Rad’s offering of anti-idiotypic antibodies continues to grow and is one of the largest portfolios available that includes antibodies targeting immune checkpoint inhibitor drugs: nivolumab and pembrolizumab and now, ipilimumab,” said Amanda Turner, Bio-Rad Product Manager, Life Science Group. “The in vitro production means researchers can rely on our highly specific and high affinity recombinant monoclonal antibodies to deliver consistent results across PK assays,” she added.

The anti-ipilimumab antibodies are approved for in vitro research and for commercial applications of in vitro testing services that support preclinical and clinical drug and biosimilar development and patient monitoring.

For more information about Bio-Rad’s anti-ipilimumab antibodies, please visit https://www.bio-rad-antibodies.com/anti-ipilimumab-antibody-yervoy.html